Janux Therapeutics, Inc. (JANX): Price and Financial Metrics
JANX Price/Volume Stats
| Current price | $56.83 | 52-week high | $71.71 |
| Prev. close | $56.75 | 52-week low | $7.79 |
| Day low | $55.63 | Volume | 1,251,800 |
| Day high | $59.72 | Avg. volume | 788,634 |
| 50-day MA | $53.95 | Dividend yield | N/A |
| 200-day MA | $46.92 | Market Cap | 2.98B |
JANX Stock Price Chart Interactive Chart >
Janux Therapeutics, Inc. (JANX) Company Bio
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
JANX Price Returns
| 1-mo | 22.22% |
| 3-mo | 13.21% |
| 6-mo | 31.49% |
| 1-year | 437.65% |
| 3-year | 181.20% |
| 5-year | N/A |
| YTD | 429.64% |
| 2023 | -18.53% |
| 2022 | -33.25% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...